Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer
Status:
Withdrawn
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
This is a two-stage phase II study with a single arm design. It will be conducted in women
with breast cancer with stages IIA to IIIC (defined by AJCC 2009 classification) of all
histological subtypes. All patients will receive 16 doses of paclitaxel; three breast
ultrasound tests and tumor pathologic response evaluation will be used to assess the response
to treatment.